Vital Therapies (VTL) Tops Q2 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Vital Therapies (VTL) Tops Q2 EPS by 3c

Pre-Open Movers 08/06: (SEAS) (VTL) (CTWS) Higher; (OVID) (BID) (PX) Lower (more...)

August 6, 2018 9:27 AM EDT

Today's Pre-Open Movers

Ovid Therapeutics Inc. (NASDAQ: OVID) 27% LOWER; announced that the Phase 2 STARS trial of OV101 achieved its primary endpoint of safety and tolerability. The investigational medicine showed a favorable safety profile and was well tolerated in adults and adolescents with Angelman syndrome. OV101 is the only selective extrasynaptic GABAA receptor agonist in development shown to mediate tonic inhibition, a key underlying pathophysiological mechanism of Angelman syndrome. Ovids founder, president and chief scientific officer, Matthew During, M.D., DSc, FACP, will present the data today at the 2018 Angelman Syndrome... More

UPDATE: William Blair Upgrades Vital Therapies (VTL) to Outperform

August 6, 2018 4:58 AM EDT

(Updated - August 6, 2018 8:14 AM EDT)

(updated to expand analyst comment)

William Blair upgraded Vital Therapies (NASDAQ: VTL) from Market Perform to Outperform.

Analayst Y. Katherine Xu is incrementally more positive on the equity ahead of VTL-308 readout scheduled for... More